Paradoxical echinocandin activity: A limited in vitro phenomenon?

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Wiederhold, Nathan P ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aspergillosis; Aspergillus fumigatus; Echinocandins; Paradoxical effect

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ANIDULAFUNGIN; CASPOFUNGIN; CHITIN; CILOFUNGIN; ECHINOCANDIN; ECHINOCANDIN B; GALACTOMANNAN; MICAFUNGIN; PROTEIN KINASE C; ANTIFUNGAL AGENT;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CELL DAMAGE; CELL WALL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG EDEMA; MICROBIAL ATTENUATION; NONHUMAN; PARADOXICAL DRUG REACTION; PROTEIN CONTENT; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; CANDIDA; DRUG EFFECT; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; REVIEW;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; CANDIDA;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY;

EID: 67651083809     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802428542     Document Type: Article

References (55)

1. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-1489.
2. Wiederhold NP, Lewis RE. The echinocandin antifungals: An overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003; 12: 1313-1333.
3. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
4. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 2007; 369: 1519-1527.
5. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356 2472-2482.
6. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
7. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-299.
8. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39 797-802.
9. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-349.
10. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 47-51.
11. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331-1336.
12. Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1187-1192.
13. Gumbo T, Drusano GL, Liu W, et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968-974.
14. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-1471.
15. Gumbo T, Drusano GL, Liu W, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006; 50: 3695-3700.
16. Andes D, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 539-550.
17. Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-5068.
18. Hall GS, Myles C, Pratt KJ, Washington JA. Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob Agents Chemother 1988; 32 1331-1335.
19. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of Echinocandins across Candida species in vitro: Evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51: 2257-2259.
20. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46: 3634-3636.
21. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081-3088.
22. Seidler M, Salvenmoser S, Muller FM. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int J Antimicrob Agents 2006; 28: 568-573.
23. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: Possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49: 5146-5148.
24. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 3407-3411.
25. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008; 52: 321-328.
26. Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005; 43(Suppl. 1): S299-305.
27. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Eaglelike effect of caspofungin against Candida and Aspergillus spp.: association with homeostatic mechanisms of cell wall integrity. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 30 October - 2 November 2004; Washington, DC; 2004M-1682.
28. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-4833.
29. Pringle JR, Preston RA, Adams AE, et al. Fluorescence microscopy methods for yeast. Methods Cell Biol 1989; 31: 357-435.
30. Coen M, Bodkin J, Power D, et al. Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy. Antimicrob Agents Chemother 2006; 50: 4018-4026.
31. Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 2005; 51: 173-178.
32. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50: 3160-3161.
33. Stevens DA, Horiuchi H, Tsuizaki M, Martinez M, Tong A. Not just for beta-1,3-glucan any more: Caspofungin inhibition of b-1,6-glucan demonstrated at inhibitory caspofungin concentrations. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago, IL; 2007, M-1813.
34. Pfaller M, Riley J, Koerner T. Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans. Eur J Clin Microbiol Infect Dis 1989; 8: 1067-1070.
35. Wiederhold NP, Wickes BL, Patterson TP. Increased gene expression of mitogen-activated protein kinase A is associated with attenuated caspofungin activity in Aspergillus fumigatus. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006; San Francisco, CA; 2006: M-364.
36. Kraus PR, Fox DS, Cox GM, Heitman J. The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin function. Mol Microbiol 2003; 48: 1377-1387.
37. Fox D, Smulian AG. Mitogen-activated protein kinase Mkp1 of Pneumocystis carinii complements the slt2Delta defect in the cell integrity pathway of Saccharomyces cerevisiae. Mol Microbiol 1999; 34: 451-462.
38. Bussink HJ, Osmani SA. A mitogen-activated protein kinase (MPKA) is involved in polarized growth in the filamentous fungus, Aspergillus nidulans. FEMS Microbiol Lett 1999; 173: 117-125.
39. Mizutani O, Nojima A, Yamamoto M, et al. Disordered cell integrity signaling caused by disruption of the kexB gene in Aspergillus oryzae Eukaryot Cell 2004; 3: 1036-1048.
40. Reinoso-Martin C, Schuller C, Schuetzer-Muehlbauer M, Kuchler K. The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot Cell 2003; 2: 1200-1210.
41. Agarwal AK, Rogers PD, Baerson SR, et al. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem 2003; 278: 34998-35015.
42. 2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol 2007; 63: 1399-1413.
43. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
44. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-1869.
45. Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867-4875.
46. Lewis RE, Albert ND, Kontoyiannis DP. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a persistently neutropenic murine model of invasive pulmonary aspergillosis. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago, IL; 2007: M-186.
47. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898-2905.
48. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echino-candin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 3381-3388.
49. van Vianen W, de Marie S, ten Kate MT, Mathot RA, Bakker-Woudenberg IA. Caspofungin: Antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57: 732-740.
50. Smith KR, Lank KM, Cobbs CG, Cloud GA, Dismukes WE. Comparison of cilofungin and amphotericin B for therapy of murine candidiasis. Antimicrob Agents Chemother 1990; 34: 1619-1621.
51. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006; 50: 1293-1297.
52. Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43: E23-25.
53. Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: Treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005; 56: 594-597.
54. Maertens J, Glasmacher A, Selleslag D, et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: Results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41: E9-14.
55. Sionov E, Mendlovic S, Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2006; 53: 131-139.